Predicting risk of adverse drug reactions in older adults

Amanda Hanora Lavan and Paul Gallagher

Ther Adv Drug Saf

2016, Vol. 7(1) 11–22

DOI: 10.1177/
2042098615615472

© The Author(s), 2015.

Reprints and permissions:
[http://www.sagepub.co.uk/
journalsPermissions.nav](http://www.sagepub.co.uk/journalsPermissions.nav)

Abstract: Adverse drug reactions (ADRs) are common in older adults, with falls, orthostatic hypotension, delirium, renal failure, gastrointestinal and intracranial bleeding being amongst the most common clinical manifestations. ADR risk increases with age-related changes in pharmacokinetics and pharmacodynamics, increasing burden of comorbidity, polypharmacy, inappropriate prescribing and suboptimal monitoring of drugs. ADRs are a preventable cause of harm to patients and an unnecessary waste of healthcare resources. Several ADR risk tools exist but none has sufficient predictive value for clinical practice. Good clinical practice for detecting and predicting ADRs in vulnerable patients includes detailed documentation and regular review of prescribed and over-the-counter medications through standardized medication reconciliation. New medications should be prescribed cautiously with clear therapeutic goals and recognition of the impact a drug can have on multiple organ systems. Prescribers should regularly review medication efficacy and be vigilant for ADRs and their contributory risk factors. Deprescribing should occur at an individual level when drugs are no longer efficacious or beneficial or when safer alternatives exist. Inappropriate prescribing and unnecessary polypharmacy should be minimized. Comprehensive geriatric assessment and the use of explicit prescribing criteria can be useful in this regard.

Keywords: adverse drug reaction, inappropriate prescribing, polypharmacy, predictive value, risk assessment

Introduction

The prevalence of adverse drug reactions (ADRs) increases with age, with twice as many patients aged 65 years and older being hospitalized because of ADR-related problems than their younger counterparts [Beijer de Blaey, 2002]. Pirmohamed and colleagues, in a prospective study of 18,820 patients attending two general hospitals in the United Kingdom, found that ADRs contributed to 6.5% of admissions and 4% of bed capacity over a 6-month period, with most ADRs occurring in older patients [Pirmohamed *et al.* 2004]. Kongkaew and colleagues identified ADRs in 10% of hospitalized older adults and 6.3% of younger adults [Kongkaew *et al.* 2008]. Cooper reported that 67.4% of 332 nursing home residents experienced at least one ADR over a 4-year period, many having repeated ADRs related to antipsychotic drugs, nonsteroidal anti-inflammatory drugs (NSAIDs) and insulin [Cooper, 1996]. Recent data indicate that 60% of

nursing home residents continue to experience ADRs, thus emphasizing ADRs as a pervasive problem in this vulnerable older cohort [Dilles *et al.* 2013].

More than 50% of ADR-related hospital admissions are preventable [Chan *et al.* 2001], most being attributable to diuretics, NSAIDs, antiplatelet, anticoagulant and antidiabetic drugs [Howard *et al.* 2007; Budnitz *et al.* 2011]. ADR-related hospitalizations have a median stay of 8 days [Pirmohamed *et al.* 2004]. In-hospital incident ADRs cause a 9% increase in length of stay and a 20% increase in cost of care encompassing bed consumption, laboratory and treatment costs [Khan, 2013]. An example of additional expenditure is the use of blood products which are needed in up to 20% of all ADR-related hospitalizations to treat gastrointestinal bleeding. Preventing such ADRs could reduce demand for blood products and could also impact on mortality [Rottenkolber

Correspondence to:
Paul Gallagher, PhD.

FRCPI
Department of Geriatric
Medicine, Cork University
Hospital, Wilton, Cork,
Ireland
paul.gallagher1@hse.ie

Amanda Hanora Lavan,
MB, MRCP
Department of Geriatric
Medicine, Cork University
Hospital, Wilton, Cork,
Ireland

et al. 2012]. A prospective study of 1225 ADR-related hospital admissions reported that 20 of 28 deaths were due to gastrointestinal or intracranial bleeding [Pirmohamed *et al.* 2004]. Overall ADR-related mortality in hospitalized patients ranges from 0.14% to 4.7%, death being more likely in those over 55 years and the greatest risk being in those aged 75 years and older [Pirmohamed *et al.* 2004; Lazarou *et al.* 1998; Budnitz *et al.* 2011].

ADRs can be difficult to recognize in older people as they often present with nonspecific symptoms, for example falls, fatigue, cognitive decline or constipation, all of which have several aetiologies. Falls, for example, may be secondary to chronic conditions such as osteoarthritis, visual impairment, myopathy or peripheral neuropathy. Numerous medications also independently increase the risk of falls, for example sedative hypnotics [Mets *et al.* 2010; Shuto *et al.* 2010], anti-hypertensives [Verhaeverbeke and Mets, 1997; Aronow, 2009] and antiarrhythmics [Ham *et al.* 2014]. Thus it can be difficult to precisely conclude whether or not a fall is attributable to an ADR in a multimorbid older patient who is prescribed such a drug. Nonetheless, potential ADRs should be part of every differential diagnosis in older patients. Failure to recognize an ADR may result in a prescribing cascade whereby a new drug is prescribed to treat the adverse effect of the culprit drug, thus exposing the patient to continuing risk of ADR from the culprit drug and additional risk from the newly prescribed drug [Rochon and Gurwitz, 1997]. An example of such practice is the prescription of an anticholinergic drug (e.g. biperiden) to treat the extrapyramidal effects of an antipsychotic drug (e.g. risperidone). The anticholinergic drug increases the risk of cognitive decline, orthostatic hypotension, blurred vision, constipation and urinary retention, which may adversely precipitate falls, delirium, functional and cognitive decline.

ADRs should be defined, recorded and their causality identified in order to minimize the risk of ADR recurrence and optimize outcomes for older patients. However, it can be difficult to reliably define and classify ADRs in everyday clinical practice using existing tools, particularly with regard to causality and preventability in patients with multiple contributory factors. In this narrative review article we discuss commonly used terminology, including definition, classification, causality and avoidability of ADRs. We describe the risk factors for ADRs in older adults and

highlight the challenges in identifying those at greatest risk. We examine existing ADR risk prediction tools and other approaches to minimizing ADR risk, including medication reconciliation (MR), comprehensive geriatric assessment and pharmacovigilance. Finally, we describe a practical clinical approach to identifying and reducing ADR risk in older patients.

ADRs: terminology

Definition and classification

An ADR is defined as ‘an appreciably harmful or unpleasant reaction resulting from an intervention related to the intentional use of a medicinal product, which predicts hazard from future administration and warrants prevention or specific treatment, or alteration of the dosage regimen or withdrawal of the product’ [Edwards and Aronson, 2000, p. 1255]. ADRs were traditionally classified as being either ‘type A’ (typically dose related, predictable and accounting for 80% of all ADRs) or ‘type B’ (typically nondose related, unpredictable or idiosyncratic) [Rawlins and Thompson, 1977]. However, this simplistic classification has evolved to include six definitive categories, presented with examples in Table 1 [Edwards and Aronson, 2000]. An adverse drug event (ADE) is defined as ‘any physical or mental harm resulting from medication use be it misuse, under-dosing or overdosing’ [Nebeker *et al.* 2004, pp. 797–798]. Unfortunately, the terms ADR and ADE are often used incorrectly and interchangeably, thus leading to difficulties with reporting, interpretation and comparison of epidemiological and interventional studies. Standardized definition and robust classification of ADRs is essential to correctly identify and measure their frequency, predictor variables and related outcomes.

Causality, severity and avoidability

Several standardized methods of assessing ADR causality exist, the advantages and disadvantages of each being summarized in Table 2 [Hire *et al.* 2013]. None is universally accepted or used in everyday clinical practice. No method is specifically validated for use in older patients with multiple comorbidities and multiple medications. The World Health Organization–Uppsala Monitoring Center (WHO-UMC) criteria [WHO] (Table 3) and the Naranjo criteria [Naranjo *et al.* 1981] are frequently cited in the medical

Table 1. Examples of ADRs using Edwards and Aronson classification system [Edwards and Aronson, 2000].

ADR category	Drug	ADR
Dose related (augmented)	Warfarin	Bleeding
Nondose related (bizarre)	Nonsteroidal anti-inflammatory drugs	Interstitial nephritis
Dose related and time related (chronic)	Long-term neuroleptic use	Tardive dyskinesia
Time related (delayed)	Immunosuppressant drugs	Lymphoma
Withdrawal (end of use)	Benzodiazepine	Seizure
Failure of therapy (failure)	Warfarin with carbamazepine	Reduced anticoagulant effect
ADR, adverse drug reaction.		

literature. Some of the variables required by the Naranjo criteria are difficult to apply to older patients with suspected ADR, for example it may be unethical to rechallenge if there is a high index of suspicion of ADR and risk of recurrence or harm is high. It is unethical to give placebo drugs in most jurisdictions. In addition, the Naranjo criteria do not allow for drug–drug interactions as a cause of ADR. Often, many of the required variables cannot be completed, thus making it unlikely for any older patient to score higher than ‘possible or probable’ in this causality system, thereby limiting its utility. ADRs are often subjectively classified as being mild, moderate, severe and lethal. Hartwig and colleagues robustly categorize ADR severity into seven groups according to clinical consequence, including resultant harm and intensity of medical intervention required (see Table 4) [Hartwig *et al.* 1992].

Determining the avoidability of an ADR should theoretically minimize occurrence and prevent reoccurrence. The Hallas criteria categorize ADR avoidability into four groups: definitely avoidable, possibly avoidable, unavoidable and unclassifiable [Hallas *et al.* 1990]. ADRs that are definitely or possibly avoidable are usually those in which organ dysfunction, homeostatic dysregulation, age-related changes in pharmacokinetics and pharmacodynamics and known drug–drug interactions predictably and adversely influence drug handling and response.

Risk factors for ADRs in older patients

Clinicians must be vigilant for recognized risk factors for ADRs in older patients in order to minimize their occurrence. These risk factors are briefly summarized below.

Age-related changes in pharmacokinetics and pharmacodynamics

Age-related physiological changes affect drug pharmacokinetics (absorption, distribution, metabolism and excretion) and pharmacodynamics (the study of effects of a drug on the body) [Mangoni and Jackson, 2004]. There is a reduction in lean muscle mass and water content with a relative increase in the proportion of total body fat. These changes influence the volume of distribution of many drugs (e.g. benzodiazepines, antipsychotics and opioids) which can, in turn, increase the risk of toxicity or ADR if doses are unadjusted. Benzodiazepines are lipophilic and generally have a larger volume of distribution in older patients compared with younger patients. Consequently, their elimination half life is prolonged, which can result in prolonged effect, drug accumulation, and greater potential for adverse effects including drowsiness and falls. Conversely, the volume of distribution for hydrophilic drugs (e.g. lithium) is reduced; this may result in toxicity if drug doses are not adjusted, particularly if there is concomitant renal impairment which may impede drug excretion.

Many drugs are protein bound when circulating in plasma (e.g. phenytoin and ibuprofen) and exert their effects through their free or unbound fractions. Lower serum albumin levels can therefore result in higher free or active drug fractions with greater potential for adverse effects. Serum albumin levels are often reduced by chronic illness, malnutrition and dietary changes, which can be intentional or unintentional in older patients, for example disease or drug-related anorexia, reduced oral intake because of poorly fitting dentures or restricted food consistencies in patients with dysphagia. Liver mass and perfusion decline by as much as 40% with age [Woodhouse

Table 2. Commonly cited ADR causality assessment tools.

Causality assessment tool	Description	Advantages	Disadvantages
Expert judgement/global introspection methods			
Swedish method [Wiholm, 1984]	Seven factors to assess: temporal sequence, previous information on the drug, dose relationship, response pattern to drug, rechallenge, alternative aetiological candidates, concomitant drugs Events classified as probable, possible, non-accessible or unlikely	Quick to use	Small number of causality categories with possible overlap between categories It may be difficult to obtain all required information for optimal classification
WHO-UMC causality assessment criteria [WHO]	Six different categories for causality with qualifying variables: certain, probable, possible, unlikely, conditional, unclassifiable (see Table 3)	Clinical and pharmacological variables and drug–drug interactions considered	Knowledge about medical conditions, laboratory tests and diseases required It may be difficult to obtain all required information for optimal classification
Algorithms			
Dangoumau's French method [Dangoumau <i>et al.</i> 1978]	Seven criteria: drug challenge, dechallenge, rechallenge, clinical signs, favouring factor, alternative nondrug aetiology, specific laboratory tests	Each drug is assessed separately	Time consuming
Kramer method [Kramer <i>et al.</i> 1979]	Assesses a single clinical manifestation occurring after administration of a single suspect drug	Transparent. If multiple drugs, each is assessed separately	Requires operator to have clinical/pharmacological expertise and experience
Ciba Geigy method [Venulet <i>et al.</i> 1980]	23 questions split into three sections with details of present reaction, past history of ADR, monitoring and physicians experience		Requires operator to have clinical/pharmacological expertise and experience Modest inter-rater reliability
Roussel Uclaf Causality Assessment Method (RUCAM) [Danan and Benichou, 1993]	Designed for predetermined system-based ADRs, e.g. hepatotoxicity or dermatological reaction	Organ specific	Narrow focus Poor inter-rater reliability
Maria and Victorino scale [Maria and Victorino, 1997]	Scale for diagnosing drug induced liver injury (DILI)	Good inter-rater reliability	Specific focus on DILI and immune-allergic hepatitis Physicians need to be experienced to use
Drug Interaction Probability Scale (DIPS) [Horn <i>et al.</i> 2007]	Ten questions on a binary scale to evaluate probability of drug–drug interactions as a cause of ADR		Requires user knowledge of pharmacology and potential interaction
Probabilistic methods			
Bayesian Adverse Reaction Diagnostic Instrument (BARDI) [Naranjo and Lanctot, 1992]	Developed to overcome the limitations associated with expert judgements and algorithms Six subsets: clinical trials information about the drug; odds of occurrence given patient history; temporal relationship; characteristics of event; drug dechallenge and rechallenge	Can evaluate over two possible causes at a time. The odds in favour of a particular drug causing an ADR are compared with alternative cause Computerized programme available for specific cases (MacBARDI)	Requires expertise to operate
ADR, adverse drug reaction.			

Table 3. The WHO-UMC causality criteria [WHO].

Causality	Conditions (all conditions need to be complied with for each causality criterion)
Certain	Event/laboratory test abnormality with plausible time relationship to intake of a drug Cannot be explained by disease or other drugs Response to withdrawal plausible Event definitive pharmacologically or phenomenologically Rechallenge satisfactory, if necessary
Probable	Event or laboratory test abnormality, with reasonable time relationship to drug intake Unlikely to be attributed to disease or other drugs Response to withdrawal clinically reasonable Rechallenge not required
Possible	Event or laboratory test abnormality, with reasonable time relationship to drug intake Could also be explained by disease or other drugs Information on drug withdrawal may be lacking or unclear
Unlikely	Event or laboratory test abnormality, with a time to drug intake that makes a relationship improbable Disease or other drugs provide plausible explanations
Conditional/ unclassified	Event or laboratory test abnormality More data for proper assessment needed, or Additional data under examination
Unassessable/ unclassifiable	Report suggesting an adverse reaction Cannot be judged because information is insufficient or contradictory Data cannot be supplemented or verified
UMC, Uppsala Monitoring Center; WHO, World Health Organization.	

Table 4. Hartwig and Siegel severity criteria [Hartwig *et al.* 1992].

Severity grade	
1	An ADR occurred but no change in treatment with suspected drug
2	The ADR required that treatment with the suspected drug be held, discontinued or otherwise changed. No antidote or other treatment required. No increase in length of stay
3	The ADR required that treatment with the suspected drug be held, discontinued or otherwise changed, or an antidote or other treatment. No increase in length of stay
4	Any level 3 ADR which increases length of stay by at least one day or the ADR was the reason for admission
5	Any level 4 ADR which required intensive medical care
6	Any ADR causing permanent harm to the patient
7a	The ADR was indirectly linked to the death of the patient
7b	The ADR was directly linked to the death of the patient
ADR, adverse drug reaction.	

and Wynne, 1988], thereby impacting on drugs with a high hepatic extraction ratio, for example diltiazem, opiates and warfarin. Such drugs will have reduced first pass metabolism with consequent increase in systemic bioavailability and greater potential for higher serum drug levels and enhanced drug effect in older patients.

Prescribers must be aware of potential interactions between drugs that are metabolized by the hepatic cytochrome p450 enzyme system [Doan *et al.* 2013; Dolder *et al.* 2010]]. This is particularly relevant to older patients receiving multiple drugs, for example coprescription of haloperidol and amitriptyline. In this instance, haloperidol can impede the

metabolism of amitriptyline through inhibition of cytochrome P450 2D6, thereby increasing the potential for anticholinergic side effects and orthostatic hypotension, which may contribute to falls and injury. Lists of cytochrome P450 enzyme inhibitors and inducers are readily available in most pharmacological texts. Glomerular filtration rate (GFR) declines with ageing because of reductions in renal size, perfusion and nephron function, which can be potentiated by diseases such as hypertension, diabetes and heart failure [Gottdiener *et al.* 2000]. Calculation of GFR is recommended for renally eliminated drugs, for example dabigatran or metformin, particularly in the context of acute illness when an acute deterioration in renal function may occur and medications may need to be adjusted or stopped accordingly in order to minimize the risk of an ADR.

Older patients are often more sensitive to the effects of medications than their younger counterparts because of altered pharmacodynamic responses. Common examples include excessive sedation and confusion with morphine, increased anticoagulant effect with warfarin, greater sensitivity to central nervous system effects of anticholinergic drugs and increased confusion with neuroleptics when used at 'standard' treatment doses. Such pharmacodynamic responses are generally predictable and can be minimized by starting at the lowest possible dose and titrating to response.

Polypharmacy and inappropriate prescribing

Older patients are the major consumers of medications in most developed nations [Wynne and Blagburn, 2010; National Center for Health Statistics, 2013]. They have a higher prevalence of chronic disease and comorbidity [Salive, 2013] often requiring more medication to multiple illnesses, thus increasing ADR risk through drug–drug and drug–disease interactions. Polypharmacy, commonly defined as the use of multiple drugs, or more than are clinically indicated, is strongly predictive of ADRs [Hajjar *et al.* 2003; Viktil *et al.* 2007]. Goldberg and colleagues reported that patients taking two concurrent medications have a 13% risk of an adverse drug interaction, rising to 38% for four medications and 82% for seven or more medications prescribed simultaneously [Goldberg *et al.* 1996]. The highest rate of polypharmacy occurs in nursing home residents [Maher *et al.* 2014], so it is

not surprising that ADRs are more prevalent in this group [Hajjar *et al.* 2007].

Inappropriate prescribing (IP) (the use of medications that pose more risk than benefit when safer alternatives exist) is highly prevalent in older patients. Approximately 50% of older adults take one or more medications that are not medically necessary [Maher *et al.* 2014]. IP has been identified in 12–40% of nursing home residents [Willcox *et al.* 1994] and 14–23% of community-dwelling older people [Ennis and Reichard, 1997]. The association between IP and ADRs is well established, Lindley and colleagues showing that 50% of ADRs in older adults are due to inappropriate prescribing [Lindley *et al.* 1992]. A significant association has also been found between IP, ADEs, acute hospitalization, death [Klarin *et al.* 2005; Lau *et al.* 2005] and higher healthcare costs [Chiatti *et al.* 2012].

Explicit criteria aim to identify IP in older adults, the most frequently cited being Beers criteria [Beers *et al.* 1991; Beers 1997; Fick *et al.* 2003; AGS, 2012] and STOPP/START criteria (Screening Tool of Older Persons Prescriptions/Screening Tool to Alert doctors to the Right Treatment) [Gallagher and O'Mahony, 2008; O'Mahony *et al.* 2015]. Such criteria comprise lists of drugs that should be avoided or used with caution in older adults, either independent of clinical condition, considering clinical condition or considering coprescribed medications. Potentially inappropriate medications listed in STOPP criteria, unlike those listed in Beers criteria, are significantly associated with avoidable ADEs in older people that cause or contribute to urgent hospitalization [odds ratio 1.8; 95% confidence interval (CI) 1.5–2.3] when adjusted for age, sex, burden of comorbidity, dementia, baseline functional status and number of medications [Hamilton *et al.* 2011]. A recent randomized controlled study showed that application of STOPP/START criteria to patients aged 65 years and older within 72 h of hospital admission results in an 11% absolute risk reduction in in-hospital ADEs [O'Connor, 2013]. These criteria have the potential to reduce IP and related ADEs but more randomized controlled studies in various clinical settings are required. In addition, explicit criteria can be time consuming to apply in everyday clinical practice and need regular updating in line with emerging literature.

Sex

Women have a 1.5 to 1.7 fold increased risk of developing an ADR compared with men [Rademaker, 2001]. This can be attributed to gender differences in immunological and hormonal physiology which influence pharmacodynamic and pharmacokinetic response, particularly in relation to cardiac and psychotropic medications [Soldin *et al.* 2011].

Genetic predisposition

Genetic factors are thought to play a role in serious ADRs that have been traditionally classified as idiosyncratic, for example drug-induced liver injury, statin-induced myotoxicity and drug-induced long QT syndrome [Wilke *et al.* 2007]. Genotyping at an individual level has the potential to optimize drug therapy thereby reducing ADRs [Meyer 2000]. This technology can be used to predict ADR risk in patients needing phenytoin, a widely used antiepileptic agent with a narrow therapeutic index and large variability in patient response. Such variability is partly due to variation in expression of the gene encoding the cytochrome P450 2C9 enzyme that metabolizes phenytoin. Recently published guidelines about the interpretation of genotyping are useful for drug dosing and could potentially reduce the occurrence of severe ADRs, such as Stevens Johnson syndrome [Caudle *et al.* 2014].

ADR prediction tools

A recent systematic review identified and assessed the quality of validated ADR risk-prediction tools for use in adults over 65 years of age [Stevenson *et al.* 2014]. Four tools were identified from the literature; three related to ADRs [Onder *et al.* 2010; Tangiisuran 2009; McElnay *et al.* 1997] and one related to ADEs [Trivalle *et al.* 2011]. The three ADR prediction tools included dedicated development and validation phases but none addressed clinical impact or implementation, thereby limiting universal applicability. Stevenson and colleagues concluded that all of the ADR prediction tools had weaknesses with regard to definition and handling of predictor variables, and that all of the ADR risk prediction models had poor to modest performance [Stevenson *et al.* 2014].

The GerontoNet ADR risk prediction tool was developed on the basis of a large Italian database

in which 383 of 5936 patients had an ADR (6.5%) [Onder *et al.* 2010]. The tool incorporates the following predictor variables: at least four comorbid conditions, heart failure, liver disease, number of drugs, history of ADR and presence of renal failure. When applied prospectively in a validation study of 483 patients, it correctly predicted ADRs in 71% of cases (95% CI 0.68–0.73) [Onder *et al.* 2010]. In a separate study, O'Connor and colleagues prospectively applied the GerontoNet risk score in an Irish hospital setting but found it incorrectly classified 38% of patients as being at low risk of developing an ADR [O'Connor *et al.* 2012]. ADR prediction models should ideally be tested on representative samples of a target population to determine clinical impact before widespread implementation.

A large number of variables contribute to ADR occurrence in older patients, thus rendering it difficult to develop a robust ADR prediction tool that is applicable to a heterogeneous population, that is a single tool is unlikely to correctly predict every ADR in every older patient. Therefore, ADR risk prediction strategies should focus either on commonly encountered harmful ADRs in all older patients (e.g. cognitive deterioration, orthostatic hypotension, falls, gastrointestinal or intracranial bleeding) or ADRs in older patients with a particular illness or clinical characteristic (e.g. renal impairment or dementia). Sharif-Askari and colleagues devised a tool to predict ADRs in hospitalized patients with chronic kidney disease (CKD) [Sharif-Askari *et al.* 2014]. This prospective, observational study evaluated patients with CKD stages 3–5, admitted to a renal unit. Baseline data were collected on all patients, the outcome being an ADR. A favourable C statistic of 0.84 was reported, that is ADRs were correctly predicted 84% of the time [Sharif-Askari *et al.* 2014]. Similar ADR risk prediction tools could be developed for patients with conditions such as dementia, delirium, orthostatic hypotension and falls.

Other strategies to minimize ADR risk in older adults

MR is a process of obtaining a patient's medication list and accurately clarifying what the patient is taking, including over-the-counter (OTC) and herbal medicinal products. The Structured History-taking of Medication (SHiM) tool can be used for this purpose [Drenth-van Maanen *et al.*

2011]. It can identify discrepancies in all aspects of medication use in older patients e.g. differences between prescribed dose and dispensed dose, inappropriate formulations, intolerances, poor adherence and use of clinically relevant non-prescribed drugs, all of which can contribute to ADRs [Prins *et al.* 2013]. Medication review of hospitalized patients by a pharmacist or doctor can reduce future emergency contacts in the short term [Christensen and Lundh, 2013]. It can also identify and resolve unintentional discrepancies at care transition points, for example hospital discharge to nursing home [Kwan *et al.* 2013]. MR is resource intensive but its greatest benefit is likely to be in those at greatest risk of ADR, that is older patients on multiple medications.

Comprehensive Geriatric Assessment (CGA) uses a multidisciplinary approach to determine medical, psychological and functional capabilities of a frail older person. It aims to develop an individualized plan for a patient's treatment and follow up. CGA can improve the quality of prescribing in older adults, Saltvedt and colleagues reporting a lower prevalence of drug–drug interactions (28% in patients with CGA intervention *versus* 43% in those with usual hospital care) and anticholinergic drug use (3% *versus* 9% respectively) at time of hospital discharge [Saltvedt *et al.* 2005]. CGA in the emergency department followed by appropriate interventions can improve outcomes in high-risk patients [Graf *et al.* 2011]. One study by Schmader and colleagues showed a 35% reduction in the risk of serious ADE compared with usual outpatient geriatric care (relative risk 0.65, 95% CI 0.45–0.93) [Schmader *et al.* 2004]. However, the success of an in-hospital intervention requires ongoing involvement of the primary care physician post discharge, thereby limiting the potential for sustained effectiveness of such intervention. Indeed, one study reported reintroduction at 1-year follow up of one in four drugs that had been previously been stopped by CGA [Lampela *et al.* 2010]. CGA is time consuming and resource intensive and thus its application is only feasible for older patients attending hospital-based geriatric medicine services.

Pharmacovigilance pertains to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problem [Morin *et al.* 2015] with the aim of enhancing medication safety and patient care. E-pharmacovigilance (where a computer links a

patient's medications with their laboratory results) can inform prescribers of potential ADRs in the setting of abnormal laboratory values [Neubert *et al.* 2013]. This represents an important step towards a systematic drug safety process but requires clinician engagement, intensive resources and regular updates. Electronic prescribing and computerized alerts can provide guidance to a prescriber about dosage errors, transcription errors, potential drug interactions and drug monitoring. A recent systematic review concluded that electronic prescribing can reduce medical errors and ADEs, though there was wide variation in study design, quality and results [Ammenwerth *et al.* 2008].

A practical approach to assessing and preventing ADRs in everyday clinical practice

Diagnosing and managing ADRs in older patients requires physician awareness of physiology and pharmacology of aging. Physicians should have a high index of suspicion for ADRs in all older patients, particularly those who develop new symptoms after starting or dose adjusting a medication, or in those presenting with cognitive or functional decline. Similarly, ADRs should be considered as a cause of new symptoms in older patients with renal impairment, falls, orthostatic hypotension, heart failure, delirium, polypharmacy and previous history of ADR [Chan *et al.* 2001]. Sufficient time should be allotted for clinical assessment, detailed medication review (including prescribed and over-the-counter drugs) and supporting collateral history where necessary. Medication lists should be assessed in the context of a patient's list of comorbid illnesses. Therapeutic duplication should be avoided, unnecessary medications discontinued and dosing frequency of remaining drugs should be optimized. Consideration should be given to medications that were prescribed at a younger age that may not have been adjusted for age-related pharmacodynamic sensitivity or for changes in renal or hepatic function.

Clear therapeutic goals should be established when starting a new medication and a date for review of efficacy and potential adverse reactions should be set. Medications which have not resulted in therapeutic benefit should not be used indefinitely, for example cognitive enhancing drugs for dementia. The use of antipsychotics, antihistamines, benzodiazepines, anticholinergic and

hypnotic drugs should be limited to reduce the risk of falls. Drugs with a narrow therapeutic index should be avoided when possible. Prescribing appropriateness criteria such as STOPP/START and Beers criteria can be useful when selecting and reviewing medications in the context of a patient with multimorbidity, though these are not intended to replace clinical judgement.

In general, drugs should be started at the lowest possible dose and slowly uptitrated according to response. Only one new medication should be commenced at any one time. Clear concise information should be given to older patients and their carers about new medications, dose alterations, monitoring requirements and potential ADR-related symptoms, including the time frame in which they are most likely to occur. Stringent application of generic practice guidelines may not be appropriate for frail older patients with limited life expectancy. Indeed, quality of life outcomes and patient preference should take precedence over routine implementation of such guidelines. Similarly, clinicians should avoid treating every symptom with a medication, particularly because the symptom in question may be an adverse effect of another coprescribed medication. In some cases, it is appropriate to avoid prescribing new medications altogether, particularly when the intended clinical outcome is unlikely to be realized.

Conclusion

ADRs are a common clinical problem in older adults and contribute significantly to morbidity and mortality. They are often unrecognized in complex older patients because of competing contributory diagnoses and poor awareness amongst treating physicians. Furthermore, the terminology of ADRs can be confusing and existing causality and severity criteria can be prohibitively difficult to apply in everyday practice. A number of ADR risk prediction tools have been published, but none are universally accepted and none are used routinely in clinical practice. Robust ADR risk prediction tools should be aspired to. However, given the heterogeneity of the older population, research efforts should focus on either predictor variables for specific patient groups (e.g. those at risk of falls or those with cognitive impairment) or predictor variables for specific ADRs, for example bleeding, hypotension or hypoglycaemia.

Detecting and predicting ADRs in older patients is based on monitoring and regular review of

prescribed and over-the-counter medicines. ADRs are a common cause of cognitive or functional decline, falls, gastrointestinal bleeding, heart failure and orthostatic hypotension. Clinicians should consider potential ADRs as part of every differential diagnosis. New medicines should be prescribed with a clear therapeutic goal. Medicines which are ineffective or no longer indicated should be deprescribed. Standardized tools, for example 'appropriateness criteria' or 'risk prediction tools' are useful adjuncts but do not replace sound clinical judgement underpinned by training in geriatric pharmacotherapy.

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Conflict of interest statement

The authors declare no conflict of interest in preparing this article.

References

- AGS (2012) American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. *J Am Geriatr Soc* 60: 616-631.
- Ammenwerth, E., Schnell-Inderst, P., Machan, C. and Siebert, U. (2008) The effect of electronic prescribing on medication errors and adverse drug events: a systematic review. *J Am Med Inform Assoc* 15: 585-600.
- Aronow, W. (2009) Treating hypertension in older adults: safety considerations. *Drug Saf* 32: 111-118.
- Beers, M. (1997) Explicit criteria for determining potentially inappropriate medication use by the elderly. An update. *Arch Intern Med* 157: 1531-1536.
- Beers, M., Ouslander, J., Rollinger, I., Reuben, D., Brooks, J. and Beck, J. (1991) Explicit criteria for determining inappropriate medication use in nursing home residents. UCLA Division of Geriatric Medicine. *Arch Intern Med* 151: 1825-1832.
- Beijer, H. and de Blaey, C. (2002) Hospitalizations caused by adverse drug reactions (ADR): a meta-analysis of observational studies. *Pharm World Sci* 24: 46-54.
- Budnitz, D., Lovegrove, M., Shehab, N. and Richards, C. (2011) Emergency hospitalizations for adverse drug events in older Americans. *N Engl J Med* 365: 2002-2012.

- Caudle, K., Doan, J., Zakrzewski-Jakubiak, H., Roy, J., Turgeon, J. and Tannenbaum, C. (2014) Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing. *Clin Pharmacol Ther* 96: 542-548.
- Chan, M., Nicklason, F. and Vial, J. (2001) Adverse drug events as a cause of hospital admission in the elderly. *Intern Med* 31: 199-205.
- Chiatti, C., Bustacchini, S., Furneri, G., Mantovani, L., Cristiani, M., Misuraca, C. *et al.* (2012) The economic burden of inappropriate drug prescribing, lack of adherence and compliance, adverse drug events in older people: a systematic review. *Drug Saf* 35(Suppl. 1): 73-87.
- Christensen, M. and Lundh, A. (2013) Medication review in hospitalised patients to reduce morbidity and mortality. *Cochrane Database Syst Rev* 2: CD008986.
- Cooper, J. (1996) Probable adverse drug reactions in a rural geriatric nursing home population: a four-year study. *J Am Geriatr Soc* 44: 194-197.
- Danan, G. and Benichou, C. (1993) Causality assessment of adverse reactions to drugs – I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. *J Clin Epidemiol* 46: 1323-1330.
- Dangoumau, J., Evreux, J. and Jouglard, J. (1978) Method for determination of undesirable effects of drugs. *Therapie* 33: 373-381.
- Dilles, T., Vander Stichele, R., Van Bortel, L. and Elseviers, M. (2013) The development and test of an intervention to improve ADR screening in nursing homes. *J Am Med Dir Assoc* 14: 371-376.
- Doan, J., Zakrzewski-Jakubiak, H., Roy, J., Turgeon, J. and Tannenbaum, C. (2013) Prevalence and risk of potential cytochrome P450-mediated drug-drug interactions in older hospitalized patients with polypharmacy. *Ann Pharmacother* 47: 324-332.
- Dolder, C., Melson, M. and Stump, A. (2010) Pharmacological and clinical profile of newer antidepressants: implications for the treatment of elderly patients. *Drugs Aging* 27: 625-640.
- Drenth-van Maanen, A., Spee, J., Van Hensbergen, L., Jansen, P., Egberts, T. and Van Marum, R. (2011) Structured history taking of medication use reveals iatrogenic harm due to discrepancies in medication histories in hospital and pharmacy records. *J Am Geriatr Soc* 59: 1976-1977.
- Edwards, I. and Aronson, J. (2000) Adverse drug reactions: definitions, diagnosis, and management. *Lancet* 356: 1255-1259.
- Ennis, K. and Reichard, R. (1997) Maximizing drug compliance in the elderly. Tips for staying on top of your patients' medication use. *Postgrad Med* 102: 211-213, 218, 223-224.
- Fick, D., Cooper, J., Wade, W., Waller, J., Maclean, J. and Beers, M. (2003) Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. *Arch Intern Med* 163: 2716-2724.
- Gallagher, P. and O'Mahony, D. (2008) STOPP (Screening Tool of Older Persons' potentially inappropriate Prescriptions): application to acutely ill elderly patients and comparison with Beers' criteria. *Age Ageing* 37: 673-679.
- Goldberg, R., Mabee, J., Chan, L. and Wong, S. (1996) Drug-drug and drug-disease interactions in the ED: analysis of a high-risk population. *Am J Emerg Med* 14: 447-450.
- Gottdiener, J., Arnold, A., Aurigemma, G., Polak, J., Tracy, R., Kitzman, D. *et al.* (2000) Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. *J Am Coll Cardiol* 35: 1628-1637.
- Graf, C., Zekry, D., Giannelli, S., Michel, J. and Chevalley, T. (2011) Efficiency and applicability of comprehensive geriatric assessment in the emergency department: a systematic review. *Aging Clin Exp Res* 23: 244-254.
- Hajjar, E., Cafiero, A. and Hanlon, J. (2007) Polypharmacy in elderly patients. *Am J Geriatr Pharmacother* 5: 345-351.
- Hajjar, E., Hanlon, J., Artz, M., Lindblad, C., Pieper, C., Sloane, R. *et al.* (2003) Adverse drug reaction risk factors in older outpatients. *Am J Geriatr Pharmacother* 1: 82-89.
- Hallas, J., Harvald, B., Gram, L., Grodum, E., Broesen, K., Haghfelt, T. *et al.* (1990) Drug related hospital admissions: the role of definitions and intensity of data collection, and the possibility of prevention. *J Intern Med* 228: 83-90.
- Ham, A., Swart, K., Enneman, A., van Dijk, S., Oliai Araghi, S., van Wijngaarden, J. *et al.* (2014) Medication-related fall incidents in an older, ambulant population: the B-PROOF study. *Drugs Aging* 31: 917-927.
- Hamilton, H., Gallagher, P., Ryan, C., Byrne, S. and O'Mahony, D. (2011) Potentially inappropriate medications defined by STOPP criteria and the risk of adverse drug events in older hospitalized patients. *Arch Intern Med* 171: 1013-1019.
- Hartwig, S., Siegel, J. and Schneider, P. (1992) Preventability and severity assessment in reporting adverse drug reactions. *Am J Hosp Pharm* 49: 2229-2232.

- Hire, R., Kinage, P. and Gaikwad, N. (2013) Causality assessment in pharmacovigilance: a step towards quality care. *Sch J App Med Sci* 1: 386-392.
- Horn, J., Hansten, P. and Chan, L. (2007) Proposal for a new tool to evaluate drug interaction cases. *Ann Pharmacother* 41: 674-680.
- Howard, R., Avery, A., Slavenburg, S., Royal, S., Pipe, G., Lucassen, P. *et al.* (2007) Which drugs cause preventable admissions to hospital? A systematic review. *Br J Clin Pharmacol* 63: 136-147.
- Khan, L. (2013) Comparative epidemiology of hospital-acquired adverse drug reactions in adults and children and their impact on cost and hospital stay – a systematic review. *Eur J Clin Pharmacol* 69: 1985-1996.
- Klarin, I., Wimo, A. and Fastbom, J. (2005) The association of inappropriate drug use with hospitalisation and mortality. *Drugs Aging* 22: 69-82.
- Kongkaew, C., Noyce, P. and Ashcroft, D. (2008) Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies. *Ann Pharmacother* 42: 1017-1025.
- Kramer, M., Leventhal, J., Hutchinson, T. and Feinstein, A. (1979) An algorithm for the operational assessment of adverse drug reactions. Background, description, and instructions for use. *JAMA* 242: 623-632.
- Kwan, J., Lo, L., Sampson, M. and Shojania, K. (2013) Medication reconciliation during transitions of care as a patient safety strategy: a systematic review. *Ann Intern Med* 158: 397-403.
- Lampela, P., Hartikainen, S., Lavikainen, P., Sulkava, R. and Huupponen, R. (2010) Effects of medication assessment as part of a comprehensive geriatric assessment on drug use over a 1-year period: a population-based intervention study. *Drugs Aging* 27: 507-521.
- Lau, D., Kasper, J., Potter, D., Lyles, A. and Bennett, R. (2005) Hospitalization and death associated with potentially inappropriate medication prescriptions among elderly nursing home residents. *Arch Intern Med* 165: 68-74.
- Lazarou, J., Pomeranz, B. and Corey, P. (1998) Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. *JAMA* 279: 1200-1205.
- Lindley, C., Tully, M., Paramsothy, V. and Tallis, R. (1992) Inappropriate medication is a major cause of adverse drug reactions in elderly patients. *Age Ageing* 21: 294-300.
- Maher, R., Hanlon, J. and Hajjar, E. (2014) Clinical consequences of polypharmacy in elderly. *Expert Opin Drug Saf* 13: 57-65.
- Mangoni, A. and Jackson, S. (2004) Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. *Br J Clin Pharmacol* 57: 6-14.
- Maria, V. and Victorino, R. (1997) Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. *Hepatology* 26: 664-669.
- McElnay, J., McCallion, C., Al-Deagi, F. and Scott, M. (1997) Development of a risk model for adverse drug events in the elderly. *Clin Drug Invest* 13: 47-55.
- Mets, M., Volkerts, E., Olivier, B. and Verster, J. (2010) Effect of hypnotic drugs on body balance and standing steadiness. *Sleep Med Rev* 14: 259-267.
- Meyer, U. (2000) Pharmacogenetics and adverse drug reactions. *Lancet* 356: 1667-1671.
- Morin, L., Fastbom, J., Laroche, M. and Johnell, K. (2015) Potentially inappropriate drug use in older people: a nationwide comparison of different explicit criteria for population-based estimates. *Br J Clin Pharmacol* 80: 315-324.
- Naranjo, C., Busto, U., Sellers, E., Sandor, P., Ruiz, I., Roberts, E. *et al.* (1981) A method for estimating the probability of adverse drug reactions. *Clin Pharmacol Ther* 30: 239-245.
- Naranjo, C. and Lanctot, K. (1992) A consultant's view on the role of Bayesian differential diagnosis in the safety assessment of pharmaceuticals. *Drug Inf J* 26: 593-601.
- National Center for Health Statistics. (2014) Health, United States, 2013: with special feature on prescription drugs. Report 2014-1232. Hyattsville, MD: National Center for Health Statistics.
- Nebeker, J., Barach, P. and Samore, M. (2004) Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting. *Ann Intern Med* 140: 795-801.
- Neubert, A., Dormann, H., Prokosch, H., Burkle, T., Rascher, W., Sojer, R. *et al.* (2013) E-pharmacovigilance: development and implementation of a computable knowledge base to identify adverse drug reactions. *Br J Clin Pharmacol* 76(Suppl. 1): 69-77.
- O'Connor, M. (2013) Adverse drug reactions in older people during hospitalisation: prevalence, risk factors and recognition. MD thesis, University College Cork, Ireland.
- O'Connor, M., Gallagher, P., Byrne, S. and O'Mahony, D. (2012) Adverse drug reactions in older patients during hospitalisation: are they predictable? *Age Ageing* 41: 771-776.
- O'Mahony, D., O'Sullivan, D., Byrne, S., O'Connor, M., Ryan, C. and Gallagher, P. (2015) STOPP/START criteria for potentially inappropriate

- prescribing in older people: version 2. *Age Ageing* 44: 213-218.
- Onder, G., Petrovic, M., Tangiisuran, B., Meinardi, M., Markito-Notenboom, W., Somers, A. *et al.* (2010) Development and validation of a score to assess risk of adverse drug reactions among in-hospital patients 65 years or older: the GerontoNet ADR risk score. *Arch Intern Med* 170: 1142-1148.
- Pirmohamed, M., James, S., Meakin, S., Green, C., Scott, A., Walley, T. *et al.* (2004) Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. *BMJ* 329: 15-19.
- Prins, M., Drenth-van Maanen, A., Kok, R. and Jansen, P. (2013) Use of a structured medication history to establish medication use at admission to an old age psychiatric clinic: a prospective observational study. *CNS Drugs* 27: 963-969.
- Rademaker, M. (2001) Do women have more adverse drug reactions? *Am J Clin Dermatol* 2: 349-351.
- Rawlins, M. and Thompson, J. (1977) Pathogenesis of adverse drug reactions. In: Davies, D. (ed.), *Textbook of Adverse Drug Reactions*. Oxford: Oxford University Press, pp. 10-31.
- Rochon, P. and Gurwitz, J. (1997) Optimising drug treatment for elderly people: the prescribing cascade. *BMJ* 315: 1096-1099.
- Rottenkolber, D., Schmiedl, S., Rottenkolber, M., Thuermann, P. and Hasford, J. (2012) Drug-induced blood consumption: the impact of adverse drug reactions on demand for blood components in German departments of internal medicine. *Basic Clin Pharmacol Toxicol* 111: 240-247.
- Salive, M. (2013) Multimorbidity in older adults. *Epidemiol Rev* 35: 75-83.
- Saltvedt, I., Spigset, O., Ruths, S., Fayers, P., Kaasa, S. and Sletvold, O. (2005) Patterns of drug prescription in a geriatric evaluation and management unit as compared with the general medical wards: a randomised study. *Eur J Clin Pharmacol* 61: 921-928.
- Schmader, K., Hanlon, J., Pieper, C., Sloane, R., Ruby, C., Twersky, J. *et al.* (2004) Effects of geriatric evaluation and management on adverse drug reactions and suboptimal prescribing in the frail elderly. *Am J Med* 116: 394-401.
- Sharif-Askari, F., Syed Sulaiman, S., Saheb Sharif-Askari, N. and Al Sayed Hussain, A. (2014) Development of an adverse drug reaction risk assessment score among hospitalized patients with chronic kidney disease. *PLoS One* 9: e95991.
- Shuto, H., Imakyure, O., Matsumoto, J., Egawa, T., Jiang, Y., Hirakawa, M. *et al.* (2010) Medication use as a risk factor for inpatient falls in an acute care hospital: a case-crossover study. *Br J Clin Pharmacol* 69: 535-542.
- Soldin, O., Chung, S. and Mattison, D. (2011) Sex differences in drug disposition. *J Biomed Biotechnol* 2011: 187103.
- Stevenson, J., Williams, J., Burnham, T., Prevost, A., Schiff, R., Erskine, S. *et al.* (2014) Predicting adverse drug reactions in older adults; a systematic review of the risk prediction models. *Clin Interv Aging* 9: 1581-1593.
- Tangiisuran, B. (2009) Predicting adverse drug reactions in the hospitalised elderly. PhD thesis, University of Sussex, Brighton.
- Trivalle, C., Burlaud, A. and Ducimetière, P. (2011) Risk factors for adverse drug events in hospitalized elderly patients: a geriatric score. *Eur Geriatr Med* 2: 284-289.
- Venulet, J., Ciucci, A. and Berneker, G. (1980) Standardized assessment of drug-adverse reaction associations—rationale and experience. *Int J Clin Pharmacol Ther Toxicol* 18: 381-388.
- Verhaeverbeke, I. and Mets, T. (1997) Drug-induced orthostatic hypotension in the elderly: avoiding its onset. *Drug Saf* 17: 105-118.
- Viktil, K., Blix, H., Moger, T. and Reikvam, A. (2007) Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug-related problems. *Br J Clin Pharmacol* 63: 187-195.
- WHO. The use of the WHO-UMC system for standardized case causality assessment. World Health Organization, Uppsala Monitoring Centre. Available at: <http://www.who-umc.org/graphics/4409.pdf> (accessed 30 August 2015).
- Wiholm, B. (1984) The Swedish drug-event assessment methods. Special workshop-regulatory. *Drug Inf J* 18: 267-269.
- Wilke, R., Lin, D., Roden, D., Watkins, P., Flockhart, D., Zineh, I. *et al.* (2007) Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. *Nat Rev Drug Discov* 6: 904-916.
- Willcox, S., Himmelstein, D. and Woolhandler, S. (1994) Inappropriate drug prescribing for the community-dwelling elderly. *JAMA* 272: 292-296.
- Woodhouse, K. and Wynne, H. (1988) Age-related changes in liver size and hepatic blood flow. The influence on drug metabolism in the elderly. *Clin Pharmacokinet* 15: 287-294.
- Wynne, H. and Blagburn, J. (2010) Drug treatment in an ageing population: practical implications. *Maturitas* 66: 246-250.